GU Cancers 2018 | Pembrolizumab: defining standards of care in urothelial cancer

Following the completion of the initial stages of the KEYNOTE-045 trial of pembrolizumab vs. the standard care for advanced urothelial cancer following chemotherapy (NCT02256436), clinicians have been awaiting the follow-up results to determine the level of benefit pembrolizumab treatment brings. At the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, the 2-year follow-up data from this study was presented, as discussed here by Robert Jones, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK. Prof. Jones highlights the continuing positive results observed and discusses the subgroup of patients showing great survival benefit, comparing it to the use of ipilimumab in melanoma.